Lenvatinib in Management of Solid Tumors.

Lenvatinib in Management of Solid Tumors. Oncologist. 2019 Oct 14;: Authors: Hao Z, Wang P Abstract Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma as single agent or in combination. In addition, lenvatinib has shown promise in several other tumor types including medullary, anaplastic thyroid, adenoid cystic, and endometrial cancer. Exploring synergy between angiogenic and immune checkpoint inhibitors, the lenvatinib/pembrolizumab combination is poised to become the next pair of active drugs in endometrial, lung, and gastrointestinal malignancies. Despite robust activity, the drug can be difficult to tolerate. Optimization of dose and biomarkers for prediction of efficacy and toxicities will be of great help. IMPLICATIONS FOR PRACTICE: Readers will be presented with an update on U.S. Food and Drug Administration approval of lenvatinib and suggestions for off-label use in thyroid cancer and adenoid cystic carcinomas. They will become familiarized with the common side effects, frequency, and predicators of response. In addition, they will learn that different strengths of lenvatinib are prescribed and why. Finally, readers are pointed to the latest efforts to combine lenvatinib and pembrolizumab, as well as to unresolved issues such as long-ter...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research

Related Links:

New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
Publication date: Available online 11 December 2019Source: The Lancet Global HealthAuthor(s): Adam Wagstaff, Sven NeelsenSummaryBackgroundThe goal of universal health coverage (UHC) requires that everyone receive needed health services, and that families who get needed services do not suffer undue financial hardship. Tracking progress towards UHC requires measurement of both these dimensions, and a way of trading them off against one another.MethodsWe measured service coverage by a weighted geometric average of four prevention indicators (antenatal care, full immunisation, and screening for breast and cervical cancers) and...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
os AC Abstract PURPOSE: To examine the effects of Arrabidaa chica (Bignoniacea) extract, a native plant of the Amazon known as crajiru, on a 7,12-dimethyl-1,2-benzanthracene (DMBA)-induced breast cancer model in Wistar rats. METHODS: We compared the response of breast cancer to the oral administration of A. chica extract (ACE) for 16 weeks, associated or not with vincristine. Groups: normal control; DMBA (50mg/kg v.o,) without treatment; DMBA+ACE (300 mg/kg); DMBA+vincristine. 500μg/kg injected i.p; DMBA+ACE+Vincristine 250μg/kg i.p. Imaging by microPET and fluorescence, biochemistry, oxidative stress, ...
Source: Acta Cirurgica Brasileira - Category: Surgery Authors: Tags: Acta Cir Bras Source Type: research
Triple-negative breast cancer is difficult to treat. A new study indicates that a common chemotherapy drug improves overall survival in this tumor type -- big news in cancer treatment.Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
al-Filho DC Abstract Carbohydrate antigen 125 (CA125) has long been used as an ovarian cancer biomarker. However, because it is not specific for ovarian cells, CA125 could also be used to monitor congestion and inflammation in heart disease. Acute heart failure (HF) is used to identify patients with a worse prognosis in ST-segment elevation myocardial infarction (STEMI). We aimed to determine the association of CA125 with acute HF in STEMI and to compare CA125 with N-terminal pro brain natriuretic peptide (NTproBNP) with a cross-sectional study. At admission, patients were examined to define Killip class and then ...
Source: Braz J Med Biol Res - Category: Research Authors: Tags: Braz J Med Biol Res Source Type: research
Abstract Polydatin (PD), a monocrystalline polyphenolic drug mainly found in the roots of Polygonum cuspidatum, has various pharmacological activities. Long non-coding RNAs (lncRNA) DiGeorge syndrome critical region gene 5 (DGCR5) was found to participate in the suppression of multiple cancers. Here, we proposed to study the effect of PD on myocardial infarction (MI) by inducing DGCR5. CCK-8 assay was performed to detect the viability of H9c2 cells. Flow cytometry was utilized to test apoptosis of H9c2 cells. These results determined the optimal concentration and effect time of hypoxia as well as PD. Si-DGCR5 was ...
Source: Braz J Med Biol Res - Category: Research Authors: Tags: Braz J Med Biol Res Source Type: research
In a recently published paper in theAnnals of Oncology [1], Choi et al. evaluated the strength of the evidence in the literature for the association between body mass index and 20 cancers in a manner that resembles our umbrella review on the same topic [2]. We were surprised to see that there were many discrepancies between the two assessments. The current paper used a grading scheme consisting of similar criteria used in our umbrella review, but structured the grading differently without providing a justification for this choice. Our umbrella review used a grading scheme that has been extensively applied and justified in ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 20 July 2015 Source:Clinica Chimica Acta, Volume 447 Author(s): Bin Wei , Chunmei Guo , Shuqing Liu , Ming-Zhong Sun Annexin A4 (Anxa4) is one of the Ca2+-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis, and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemoresistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemoresistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC)...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
More News: Adenoids | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Endometrial Cancer | Food and Drug Administration (FDA) | Gastroenterology | Hepatocellular Carcinoma | Kidney Cancer | Learning | Liver Cancer | Renal Cell Carcinoma | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training